18:53 , Jul 30, 2018 |  BC Extra  |  Financial News

Biopharma analyst Anderson departs Bernstein

Equity analyst Tim Anderson left the Sanford C. Bernstein research division of AllianceBernstein Holding L.P. (NYSE:AB) this month, spokesperson Angela Tu told BioCentury. Anderson was managing director of global pharmaceuticals equity research. According to his...
07:00 , Aug 3, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 7/31 cls Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) Jefferies Eun Yang Upgrade Buy (from hold) 9% $19.13 Yang upgraded, saying the resignation...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Amgen, Third Point LLC biopharmaceuticals news

Activist investor Third Point outlined a plan for increasing Amgen's valuation by more than 80% in the next two years. The firm wants Amgen to split into two companies, one for "cash-generative Mature Products" and...
07:00 , Oct 27, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/24 cls Galenica Ltd. (SIX:GALN) UBS Guillaume van Renterghem Upgrade Neutral (from sell) 5% CHF797.5 Renterghem upgraded as Galenica stock...
07:00 , Sep 15, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 9/12cls BioDelivery Sciences International Inc. (NASDAQ:BDSI) Summer Street Jim Molloy Price target Buy 11% $18.15 Molloy raised his target to...
07:00 , Jun 16, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/13 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Upgrade Outperform (from neutral) 125% $6.47 UBS Andrew Peters Upgrade Buy (from neutral) Skorney also...
01:54 , May 10, 2014 |  BC Extra  |  Financial News

Medivation up on Xtandi sales

Medivation Inc. (NASDAQ:MDVN) gained $5.11 to $65.11 on Friday after reporting 1Q14 results late Thursday, including U.S. sales of prostate cancer drug Xtandi enzalutamide that beat the Street's estimate. First quarter U.S. net sales of...
07:00 , May 5, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/2cls Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Bernstein Research Geoffrey Porges Upgrade Outperform (from market perform) 1% $155.12 Porges also raised his target to $193 from...
08:00 , Feb 10, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/7 cls Fluidigm Corp. (NASDAQ:FLDM) Cowen Doug Schenkel Downgrade Market perform (from outperform) -4% $43.11 Schenkel raised his target to $45 from $42, saying...
08:00 , Nov 4, 2013 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/1 cls Alimera Sciences Inc. (NASDAQ:ALIM) Cowen Simos Simeonidis Upgrade Outperform (from market perform) 1% $2.05 Simeonidis said Alimera is "significantly" undervalued following the...